13.70
Eloxx Pharmaceuticals Inc Aktie (ELOX) Neueste Nachrichten
Eloxx doses first patients in exaluren Alport trial - grafa.com
Eloxx doses first patients in Alport syndrome trial By Investing.com - Investing.com Canada
Eloxx doses first patients in Alport syndrome trial - Investing.com
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome - PR Newswire
Certain Warrants of Eloxx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2026. - marketscreener.com
Certain Stock Options of Eloxx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2026. - marketscreener.com
155,016 Common Stock of Eloxx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2026. - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL) - theglobeandmail.com
Eloxx Pharmaceuticals, Inc. Common Stock (OTC: ELOX) Share Price, ELOX Stock News, ELOX Share Price & Updates - kalkine.ca
Guggenheim Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Lucid Capital Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $38 - Moomoo
Eloxx Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Lucid Capital Markets initiates Eloxx Pharma stock with buy rating - Investing.com
Lucid Capital Markets initiates Eloxx Pharma stock with buy rating By Investing.com - Investing.com India
Lucid Capital Markets initiates Eloxx Pharma stock with buy rating - Investing.com
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) Share Price, ELOX Stock News, ELOX Share Price & Updates - Kalkine
Eloxx Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Equity in earnings of Eloxx Pharmaceuticals, Inc. – FWB:J36 - TradingView
Eloxx Pharmaceuticals, Inc. Statistics – FWB:J36 - TradingView
J36 Forecast — Price Target — Prediction for 2027 - TradingView
ETFs Investing in Eloxx Pharmaceuticals, Inc. Stocks - TradingView
Eloxx Pharmaceuticals, Inc. Common Stock (NASDAQ: ELOX) Stock Price, News & Analysis - kalkine.ca
Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate - Stock Titan
Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G - Stock Titan
LifeSci Capital Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Eloxx Pharmaceuticals Q2 net loss widens on higher expenses - TradingView
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - Barchart.com
Form 8K Eloxx Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Form 8K Eloxx Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Eloxx Pharmaceuticals reports Q2 2026 net loss $4.5M, $62.0M cash after $66.0M offering - TradingView
8-K: Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Eloxx Pharmaceuticals, Inc. 2Q 2026: Net loss $4.5M, EPS $(0.66) — 10-Q Summary - TradingView
ELOX: Raised $58.3M in public offering, advancing exaluren trials amid rising operating losses - TradingView
Eloxx Pharmaceuticals (NASDAQ: ELOX) boosts cash with $58.3M equity raise - stocktitan.net
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eloxx Pharmaceuticals Ord Shs (ELOX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ETFs Investing in Eloxx Pharmaceuticals, Inc. Stocks - TradingView
Biotech Stocks At 52-Week HighsANGO, ANIK, ELOX, YARW, PLSE - RTTNews
Eloxx Pharmaceuticals (ELOXD) Financials 2026Income Statement and Balance Sheet - MarketBeat
ELOXEloxx Pharmaceuticals Inc Short Interest - Finviz
abrdn Inc. (ELOX) discloses 400,000-share, 9.91% holding in Eloxx - Stock Titan
Eloxx Pharmaceuticals Ord Shs (ELOX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ELOX|Eloxx Pharmaceuticals Ord Shs|Price:11.940|Chg%:-0.060 - TradingKey
Eloxx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELOX - TradingView
ELOX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
Price to earnings forward of Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX - TradingView
ELOX stock holds on report context and clinical milestones - Ad-hoc-news.de
Eloxx Pharmaceuticals (ELOX) Q4 2025 earnings summary - Quartr
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):